References
- Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134–1143.
- Scarfo L, Chatzikonstantinou T, Rigolin GM, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European research initiative on CLL, and CLL campus. Leukemia. 2020;34(9):2354–2363.
- da Cunha-Bang C, Kirkby NS, Friis-Hansen L, et al. Serological response following vaccination with BNT162b2 mRNA in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2022;63(2):503–505.
- Corey L, Beyrer C, Cohen MS, et al. SARS-CoV-2 variants in patients with immunosuppression. N Engl J Med. 2021;385(6):562–566.
- Sung A, Bailey AL, Stewart HB, et al. Isolation of SARS-CoV-2 in viral cell culture in immunocompromised patients with persistently positive RT-PCR results. Front Cell Infect Microbiol. 2022;12:804175.
- Taha Y, Wardle H, Evans AB, et al. Persistent SARS-CoV 2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy. Ann Clin Microbiol Antimicrob. 2021;20(1):85.
- Hanssen JLJ, Stienstra J, Boers SA, et al. Convalescent plasma in a patient with protracted COVID-19 and secondary hypogammaglobulinemia due to chronic lymphocytic leukemia: buying time to develop immunity? Infect Dis Rep. 2021;13(4):855–864.
- Guisado-Vasco P, Carralón-González MM, Aguareles-Gorines J, et al. Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia. J Hematol Oncol. 2022;15(1):4.
- Helleberg M, Niemann CU, Moestrup KS, et al. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis. 2020;222(7):1103–1107.
- Istituto Superiore Sanità. Prevalenza e distribuzione delle varianti di SARS- CoV-2 di interesse per la sanità pubblica in Italia. Rapporto No. 17, 18 February 2022.
- Ai J, Wang X, He X, et al. Antibody evasion of SARS-CoV-2 omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. Cell Host Microbe. 2022;30(8):1077–1083.e4.
- Bronstein Y, Adler A, Katash H, et al. Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection. J Med Virol. 2022;94(3):1241–1245.
- Hogan JI, Duerr R, Dimartino D, et al. Remdesivir resistance in transplant recipients with persistent coronavirus disease 2019. Clin Infect Dis. 2023;76(2):342–345.
- Dioverti V, Salto-Alejandre S, Haidar G. Immunocompromised patients with protracted COVID-19: a review of "long persisters. Curr Transpl Rep. 2022;9(4):209–218.
- Graziani L, Gori L, Manciulli T, et al. Successful use of nirmatrelvir/ritonavir in immunocompromised patients with persistent and/or relapsing COVID-19. J Antimicrob Chemother. 2023;78(2):555–558.
- Trottier CA, Wong B, Kohli R, et al. Dual antiviral therapy for persistent COVID-19 and associated organizing pneumonia in an immunocompromised host. Clin Infect Dis. 2023; 76(5):923–25.
- Blennow O, Vesterbacka J, Tovatt T, et al. Successful combination treatment for persistent SARS-CoV-2 infection. Clin Infect Dis. 2023. Online Ahead of Print.
- Baldi F, Dentone C, Mikulska M, et al. Case report: sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19. Front Med (Lausanne). 2022;9:1062450.